Pulmonary Veno-Occlusive Disease: Clinical Features, Diagnosis, and Causes
PVOD should be suspected in any patient presenting with pulmonary hypertension who has the triad of subpleural septal thickening, centrilobular ground-glass opacities, and mediastinal lymphadenopathy on high-resolution CT—this combination is 100% specific for PVOD. 1
Clinical Features
Symptoms
Patients present with dyspnea on exertion and fatigue that is clinically indistinguishable from idiopathic PAH 1. However, several key features should raise suspicion:
Physical Examination Findings (Unusual in PAH)
- Digital clubbing
- Bi-basal crackles on lung auscultation 1
Laboratory Abnormalities
- Severe hypoxemia (more pronounced than other PAH forms)
- Markedly reduced DLCO (much lower than typical PAH) 1
- These findings reflect chronic interstitial pulmonary edema and pulmonary capillary proliferation characteristic of PVOD 1
Demographic Pattern
- Male predominance (contrasts with IPAH)
- Worse prognosis than IPAH 1
Diagnostic Approach
High-Resolution CT Chest (Investigation of Choice)
The classic triad with 100% specificity and 66% sensitivity 1, 2:
- Subpleural thickened septal lines
- Centrilobular ground-glass opacities (NOT panlobular distribution seen in IPAH)
- Mediastinal lymphadenopathy
Additional CT findings include Kerley B lines and peripheral interstitial infiltrate 1
Bronchoscopy with Bronchoalveolar Lavage
Useful for detecting occult alveolar hemorrhage 1:
- Elevated cell count
- Higher percentage of hemosiderin-laden macrophages
- Markedly elevated Golde score compared to IPAH 1
Genetic Testing
In heritable cases, identification of bi-allelic EIF2AK4 mutations is sufficient to confirm diagnosis without histological confirmation 1. These mutations cause the disease to segregate as a recessive trait (affecting young siblings with unaffected parents), unlike BMPR2 mutations in PAH which follow autosomal dominant inheritance 1
Right Heart Catheterization
- Hemodynamics appear similar to IPAH
- PAWP is almost invariably normal because pathological changes occur in small venulae, not larger pulmonary veins 1
- Vasoreactivity testing may precipitate acute pulmonary edema and should be avoided 1
Lung Biopsy
No longer recommended in most cases due to hazardous nature; non-invasive approach combining clinical, radiological, and bronchoscopic findings is preferred 1
Causes
Heritable Forms
- Bi-allelic EIF2AK4 mutations (recessive inheritance pattern) 1
- Accounts for familial cases and approximately 25% of sporadic cases 1
Associated Conditions
- Systemic sclerosis (SSc)
- HIV infection
- Connective tissue diseases 1
Drug and Toxin Exposures
- Cyclophosphamide
- Mitomycin (most notable chemotherapy association) 1, 3
- Organic solvents (occupational exposure) 3
Idiopathic
Approximately 10% of cases initially classified as idiopathic PAH actually fulfill criteria for PVOD/PCH 1
Critical Management Pitfall
PAH-specific vasodilators, especially IV epoprostenol, carry high risk of life-threatening pulmonary edema in PVOD patients 1. The presence of the CT triad strongly correlates with this risk 1. Therefore:
- Immediate referral to lung transplant center is indicated as soon as diagnosis is established (Class I recommendation) 2, 1
- Management only at centers with extensive PAH experience due to pulmonary edema risk (Class IIa recommendation) 2, 1
- Lung transplantation is the only curative therapy with no disease recurrence reported post-transplant 1
The median survival without transplantation is less than 2 years, making early recognition and transplant referral essential 4.